Format

Send to

Choose Destination
Prim Care Diabetes. 2019 Nov 5. pii: S1751-9918(19)30075-0. doi: 10.1016/j.pcd.2019.09.008. [Epub ahead of print]

Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes.

Author information

1
Division of Cardiology, University of Texas Health Science Center, San Antonio, TX, USA. Electronic address: chilton@uthscsa.edu.
2
Division of Endocrinology, Diabetes and Metabolism, Ohio State University, Columbus, OH, USA.
3
Touro University California College of Osteopathic Medicine, Primary Care Department, Vallejo, CA, USA.
4
Center of Diabetes and Metabolism, Emory University, Atlanta, GA, USA.

Abstract

Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in patients with type 2 diabetes (T2D). This review examines the impact of cardiovascular outcome trials (CVOTs) on clinical practice. To date, all CVOTs have shown non-inferiority versus placebo (both added to standard of care) against a primary endpoint of 3- or 4-point major adverse cardiovascular event (MACE), confirming CV safety of these treatments. Additionally, some CVOTs have shown superiority to placebo against the same MACE endpoint, suggesting a cardioprotective action for these treatments. This is reflected in guideline updates, which primary care physicians should consider when personalizing treatments.

KEYWORDS:

Antihyperglycemic; Cardiovascular outcome trials; Cardiovascular risk; Type 2 diabetes

PMID:
31704161
DOI:
10.1016/j.pcd.2019.09.008
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center